Hematology and Oncology Discovery

Hematology and Oncology Discovery is a peer reviewed, open access journal on hematology and oncology research, spanning from basic laboratory, translational to clinical investigations.  The journal aims to provide a platform for hematologists and oncologists to communicate practical experiences to facilitate real-case diagnosis and treatments as well as adoption of latest physiological and biological advances and new technologies derived, and to inspire researchers to tackle challenges from clinical settings. 

 

Hematology and Oncology Discovery

 

About

 

Hematology and Oncology Discovery is a peer reviewed, open access journal on hematology and oncology research, spanning from basic laboratory, translational to clinical investigations.  The journal aims to provide a platform for hematologists and oncologists to communicate practical experiences to facilitate real-case diagnosis and treatments as well as adoption of latest physiological and biological advances and new technologies derived, and to inspire researchers to tackle challenges from clinical settings. Besides original research, reviews, case studies and clinical trials, the journal is particularly interested in summary of individual opinion on specific disorder facilitating clinical practice.

The journal encourages clinicians and physicians to take a holistic and multidisciplinary angle when discussing their cases and in particular, when pursuing solutions for hematologic malignancies, tumors and complications:

  • Gene therapy and application in patient care
  • Immunotherapy and Immunobiology
  • Transplantation
  • Observations on pathological discoveries, e.g., molecular pathways, genomics etc.
  • Rare diseases in hematology and oncology

Hematology and Oncology Discovery subscribes fully to the COPE code of conduct and best practice for journal editors ensuring that our editors are accountable for everything published in our journal. Our readers will always be informed about how the research is funded and our relationships with authors, reviewers and editorial board members will be influenced by COPE recommendations.

 


 

Funded By

Hematology and Oncology Discovery journal publishes as an online open access journal.

The journal is funded by GoBroad Healthcare Group:

GoBroad Healthcare Group

Address: 3-224, No 7 Changxingdiandujiakan, Fengtai District, Beijing City 100072, China

Tel: +86 10 63290612

For more information please contact:

Editorial Office, Hematology and Oncology Discovery

E-mail:   editorialoffice@hod-journal.org

 


 

Published By

The journal is published by Compuscript Ltd.

For more information please contact:

Morgan Lyons

Bay 11a, Shannon Industrial Est., Shannon, Co. Clare, Ireland

Tel: +353 61 472743

E-mail: sales@compuscript.com

 


 

Open Access

Hematology and Oncology Discovery publishes as an open access journal. This means all articles are available on the internet to all users immediately upon publication. See full licencing and copyright information here.

Article Types Published

Hematology and Oncology Discovery publishes Original Research, Review, Case Report, Clinical Trial, Disease Treatment and Letters to the Editor.

 

 

Editorial Board

 

Co-Editors-in-Chief

Dong Chen, MD, PhD, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

Lugui Qiu, MD, Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

 

Executive Editor-in-Chief

Tong Wu, MD, Beijing Boren Hospital, Beijing, China

 

 

Submit a Paper

 

Hematology and Oncology Discovery is a peer reviewed, open access journal on hematology and oncology research, spanning from basic laboratory, translational to clinical investigations.  The journal aims to provide a platform for hematologists and oncologists to communicate practical experiences to facilitate real-case diagnosis and treatments as well as adoption of latest physiological and biological advances and new technologies derived, and to inspire researchers to tackle challenges from clinical settings. Besides original research, reviews, case studies and clinical trials, the journal is particularly interested in summary of individual opinion on specific disorder facilitating clinical practice.

The journal encourages clinicians and physicians to take a holistic and multidisciplinary angle when discussing their cases and in particular, when pursuing solutions for hematologic malignancies, tumors and complications:

  • Gene therapy and application in patient care
  • Immunotherapy and Immunobiology
  • Transplantation
  • Observations on pathological discoveries, e.g., molecular pathways, genomics etc.
  • Rare diseases in hematology and oncology

Submissions to Hematology and Oncology Discovery are made using ScholarOne, the online submission and peer review system. Registration and access are available via the →Submit Button on the →Collection banner.

 

 

Instructions to Authors

 

Article Types

Hematology and Oncology Discovery welcomes the submission of Original Research, ReviewCase ReportsClinical TrialDisease Treatments, and Editorial. To download a brief summary of author ethics and malpractice guidelines when preparing text please click here.

Authors must follow these guidelines when preparing text:

The Declaration of Helsinki (DoH) for studies involve human subjects: https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/

CONSORT for randomized controlled trials: http://www.consort-statement.org/consort-2010

PRISMA for Systematic Review and Meta-analyses: http://www.prisma-statement.org/

TREND for non-randomized trials: https://www.cdc.gov/trendstatement/

CARE for case reports: http://www.care-statement.org/resources/checklist

STROBE for observational studies: https://www.strobe-statement.org/index.php?id=available-checklists

STREGA for genetic association studies: http://www.equator-network.org/reporting-guidelines/strobe-strega/

SRQR for qualitative studies: https://www.equator-network.org/reporting-guidelines/srqr/

STARD for diagnostic accuracy studies: http://www.stard-statement.org/ 

ARRIVE for animal experiments: https://www.nc3rs.org.uk/arrive-guidelines

 

Original Research

Word limit: 4,000 words maximum including abstract but excluding references, tables and figures.

Abstract: 300 words maximum, including background, methods, results and conclusions.

References: we recommend a limit of 100 references.

Figures/Tables: There is no limit on the number of figures and tables that can be included, however we recommend 5-10 figures/ tables per article.

Description: include abstract, introduction, methods, results, discussion, acknowledgements, disclosure of conflicts of interest and references. Supplemental data may include additional information regarding methodology, supplemental figures or tables, or primary data sets. Graphical Abstracts and Highlights are mandatory for Original Research.

Case Report

Word limit: 2,000 words maximum including abstract but excluding references, tables and figures.

Abstract: 200 words maximum, including background, methods, results and conclusions.

References: we recommend a limit of 50 references.

Figures/Tables: There is no limit on the number of figures and tables that can be included, however we recommend 2-10 figures/ tables per case report.

Description: on findings from either the clinic or the laboratory that are novel, but not necessarily definitive, scientific observations. Designed to stimulate new insight and next steps in translational or basic research. Include abstract, introduction, methods, results and discussion, acknowledgements, disclosure of conflicts of interest and references.

Review

Word limit: 5,000 words maximum including abstract but excluding references, tables and figures.

Abstract: 300 words maximum

References: we recommend a limit of 100 references.

Figures/Tables: There is no limit on the number of figures and tables that can be included,

Description: focus on recent scientific or clinical advances in an area of broad interest to those in the field. Reviews are encouraged to be concise and critical and include appropriate references to the literature. Authors are encouraged to contact Co-Editors-in-Chief or the Editorial Office before submission. The journal accepts systematic review, and authors who wish to submit a systematic review (meta-analysis) need to contact Co-Editors-in-Chief or the Editorial Office before submission.

Clinical Trial

Word limit: 4,000 words maximum including abstract but excluding references, tables and figures.

Abstract: 300 words maximum, including background, methods, results and conclusions.

References: we recommend a limit of 100 references.

Figures/Tables: There is no limit on the number of figures and tables that can be included, however we recommend 2-10 figures/ tables per case report.

Description: describe the methodology, implementation, and results of controlled studies, usually undertaken with large patient groups. Authors conducting clinical trials need to demonstrate practical work experience, and high standards of ethics and reliability, and should follow the guidelines:

Disease Treatment

Word limit: 4,000 words maximum including abstract but excluding references, tables and figures.

Abstract: 300 words maximum, including background, methods, results and conclusions.

References: we recommend a limit of 100 references.

Figures/Tables: There is no limit on the number of figures and tables that can be included,

Description: Disease Treatments are written by expert clinicians offering up-to-date information and guidance regarding diagnosis and treatment of hematological diseases and clinical situations based on longstanding clinical experience. They focus on a specific disease with emerging treatments. Authors are encouraged to contact Co-Editors-in-Chief or the Editorial Office before submission.

Editorials

Editorials are usually invited by the Editorial Board or/and Editorial Office. Editorials are usually respond to a special issue to explain the content of the special issue, or/and to describe policy issues relevant to the journal, e.g., the launch of the journal, the change of article type etc. Editorials must be evidence based but journalistic in style, and written with an international general medical audience in mind.

 

Online Article Submission

Submissions to Hematology and Oncology Discovery are made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/hemoncdiscneeds.

Papers submitted to the Journal should present previously unpublished data or interpretations; they should not be submitted elsewhere while under editorial consideration. Manuscripts should be clear and credible in argument, have a clear hierarchy, use concise headings and have an appropriate mix of text, figures and tables. For each submission, the author should also provide the following Anti-plagiarism Form:

A separate title page including author names, affiliations and acknowledgements (these items should not be included in the main document).

Manuscripts must be submitted online by the corresponding author. Authors must provide an official e-mail address as all correspondence will be contacted through e-mail. In cases of submission difficulties, please direct your inquiries via e-mail to the Editorial Office at editorialoffice@hod-journal.org.

 

Cover Letter

A covering Letter is required. The journal encourages the authors to take the chance to explain why the manuscript will be of interest to a journal’s readers.

The following points are recommended for inclusion:

  • Briefly explain the background, the research question to be answered and the significance of your work.
  • Concisely explain what was done, the main results and why they are significant.
  • Why the Editors and readers of the journal would be interested in the work.
  • State the corresponding author and any journal specific requirements that need to be complied with, e.g. ethical standards. Here are a few sentences for reference: we confirm that this manuscript has not been published elsewhere and is not under consideration by another journal; all authors have approved the manuscript and agree with its submission to the journal.

Data Availability Statement

A Data Availability Statement tells the reader if the data behind research can be accessed and, if so, where and how.

Hematology and Oncology Discovery requires a Data Availability Statement for the following article types: Original Research, Case Report and Clinical Trial.

The journal offers the following statements and authors are required to choose one of the following:

  • The raw data required to reproduce the above findings are available to download from [INSERT PERMANENT WEB LINK(s)]. The processed data required to reproduce the above findings are available to download from [INSERT PERMANENT WEB LINK(s)].
  • The raw/processed data required to reproduce the above findings are available from the corresponding author on reasonable request.
  • The raw/processed data required to reproduce the above findings are included in this published article and as supplementary information to this article.
  • The raw/processed data required to reproduce the above findings cannot be shared at this time for legal/ethical reasons.
  • The raw/processed data required to reproduce the above findings cannot be shared at this time due to technical/time limitations.
  • The raw/processed data required to reproduce the above findings cannot be shared at this time as the data also forms part of an ongoing study.

Authors will be contacted for a Data Availability Statement after manuscript acceptance.

Figures

Authors should pay attention to the clarity and spelling of any lettering on the diagrams. All images should be supplied at 300 dpi or above, in JPG or TIF. Vector files should be in Ai, EPS or CDR format. All figures will be reduced in size to fit, wherever possible, to the width of a single column, i.e. 85 mm, or a double column, i.e. 174 mm and the height not more than 254 mm.

All illustrations should be clearly numbered with the figure number and caption clearly indicated on the bottom of the figure.

For review articles, figures taken from any published sources must obtain permission prior to publication. These figures should be cited as “Reproduced with permission from journal name, Permission number, copyright year”

Tables

Table numbers and names should be centered; table footnotes should be included at the bottom of the table; table symbols and units should be clearly designated. Authors are requested to express decimal fractions with full-stops, not commas. Tabulated ‘raw’ data should be kept to a minimum.

References

References are cited by number in the text in sequence of first appearance and listed numerically at the end of the text. The journal adheres to the Vancouver reference style. The author can use the Vancouver style that comes with the EndNote software.

Examples of style are:

Periodicals/Authored Articles

Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 2011;364:412-21. [PMID: 21247310; DOI: 10.1056/NEJMoa1008108]

Articles Authored by Organizations

Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension 2002;40:679-86 [PMID: 12411462].

Articles – Authors and Organizations

Vallancien G, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003;169:2257-61. [ PMID: 12771764; DOI: 10.1097/01.ju.0000067940.76090.73]

Non-Anglophone Standard Journal Articles

(Title should be translated into English; state original language in parentheses)

Zhang X, Xiong H, Ji TY, Zhang YH, Wang Y. Case report of anti-N-methyl-D-aspartate receptor encephalitis in child. J Appl Clin Pediatr 2012;27:1903-7 (in Chinese).

Articles Ahead of Print

(DOI must be included)

Odibo AO. Falling stillbirth and neonatal mortality rates in twin gestation: not a reason for complacency. BJOG 2018; Epub ahead of print [PMID: 30461178; DOI: 10.1111/1471-0528.15541]

Books

Sherlock S, Dooley J. Diseases of the liver and iliary system. 9th ed. Oxford: Blackwell Sci Pub; 1993. Pp. 258-96.

Chapter in a Book

Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 2002. Pp. 93-113.

Collected Articles, Proceedings, Etc./Online Resource

FDA News Release. FDA approval brings first gene therapy to the United States. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm [Last accessed on 30 Oct 2017].

Conference Proceedings

Harnden P, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ Cell Tumour Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer; 2002.

Conference Paper

Christensen S, Oppacher F. An analysis of Koza’s computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsale, Ireland. Berlin: Springer; 2002. Pp. 182-91.

Unpublished Articles

The journal does not accept citations to unpublished articles.

For other types of references please refer to U.S. National Library of Medicine.

Keywords

Keywords are mandatory for the journal, and please list your keywords in the file to be uploaded to Submission system together with the body of your article. The journal will extract the keywords from the file to include in the final publication.

Authors are also encouraged to select the keywords from the list in submission, which would be used by Handling Editor to identify appropriate reviewers for your submission, and those keywords will not appear in final publication.

Acknowledgments

Please provide the name and serial number of the project if the research is supported by a research fund or the relevant government departments or social organizations.

Disclosure

All authors must individually sign “Author Contribution and Agreement” form and acknowledge full responsibility of the submission of the manuscript. Each author must disclose all financial relationships related to the subject of the paper. This should include equity ownership, profit-sharing agreements, royalties, patents, and grants. Authors do not need to report the sums concerned. If none, state “none”.

Competing Interests

Conflict of interests (or competing interests) can be defined as factors which could influence the judgment of an author, reviewer or editors, and may be personal, commercial, political, academic, or financial in nature. Competing interests that might interfere with the objective presentation of the research findings contained in the manuscript should be declared in a paragraph heading “Competing interests” (after Acknowledgment section and before References). Examples of competing interests are ownership of stock in a company, commercial grants, board membership, etc. If there is no competing interest, please use the statement “The authors declare that they have no competing interests.” For additional guidance and information on the topic of conflict of interests and competing interests please refer to The International Committee of Medical Journal Editors (ICMJE) recommendations on author responsibility and our Publication Ethics and Malpractice Statements.

Ethics in publishing
Please see our information pages on our Publication Ethics and Malpractice Statements

 

 

Frequently Asked Questions (FAQs)

 

  1. What are the aims & scope of Hematology and Oncology Discovery?

Hematology and Oncology Discovery is a peer reviewed, open access journal on hematology and oncology research, spanning from basic laboratory, translational to clinical investigations.  The journal aims to provide a platform for hematologists and oncologists to communicate practical experiences to facilitate real-case diagnosis and treatments as well as adoption of latest physiological and biological advances and new technologies derived, and to inspire researchers to tackle challenges from clinical settings. Besides original research, reviews, case studies and clinical trials, the journal is particularly interested in summary of individual opinion on specific disorder facilitating clinical practice.

The journal encourages clinicians and physicians to take a holistic and multidisciplinary angle when discussing their cases and in particular, when pursuing solutions for hematologic malignancies, tumors and complications:

  • Gene therapy and application in patient care
  • Immunotherapy and Immunobiology
  • Transplantation
  • Observations on pathological discoveries, e.g., molecular pathways, genomics etc.
  • Rare diseases in hematology and oncology

Hematology and Oncology Discovery publishes original research articles, review articles, case reports, clinical trial reports, disease treatments and Letters to the Editor.

  • What is open access?

Hematology and Oncology Discovery is an open access journal. This means that all articles published in Hematology and Oncology Discovery are freely and universally available online.

  • How should I submit articles to Hematology and Oncology Discovery?

Submissions to Hematology and Oncology Discovery are made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/hemoncdisc

  • Do I need to pay a publication fee, and will I receive remuneration for publishing papers in Hematology and Oncology Discovery?

The journal does not impose author processing charges (APCs) or any other publication fees. We do not offer remuneration for publishing papers in Hematology and Oncology Discovery.

Submit your article today at https://mc04.manuscriptcentral.com/hemoncdisc.

  • Is there a printed version of Hematology and Oncology Discovery?

No.

  • Where can I access the online version of Hematology and Oncology Discovery

Hematology and Oncology Discovery is published online at ScienceOpen If you would like a hard copy of an article, you can download the PDF version of the article and print it.

 

 

 

 

Contact Us

 

Contact Hematology and Oncology Discovery:

 

Editorial Offices

Co-Editor-in-Chief: Dong Chen

Address:   Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

Email: dongchen@hod-journal.org

Co-Editor-in-Chief: Lugui Qiu

Address:   Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Email: luguiqui@hod-journal.org

Executive Editor-in-Chief: Tong Wu, MD

Address: 12th Floor, South Tower, Lize Soho, No. 20 Lize Road, Fengtai District, Beijing, PR China

E-mail: tongwu@hod-journal.org

 

Editorial Office

Address: 12th Floor, South Tower, Lize Soho, No. 20 Lize Road, Fengtai District, Beijing, PR China

E-mail: editorialoffice@hod-journal.org

 

Publisher

Contact: Compuscript Ltd.

Address: Bay 11a, Shannon Industrial Est., Shannon, Co. Clare, Ireland

Tel:+353 61 472743

E-mail: haibao@compuscript.com

 

Editors

Collection Information